Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Moody's Corporation (MCO) Price & Performance

Davita IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Moody's Corporation — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Moody's Corporation trades at $476.73 (market cap $82.80B). The key difference: Moody's Corporation is far larger — about 7.1× Davita Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAMCO
Market Cap
$11.72B$82.80B
Sector
HealthFinancials
52-Week High
$240.96$539.61
52-Week Low
$103.87$412.23
Enterprise Value
$24.44B$88.83B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.

The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.

Moody's Corporation

MCO trades at $477.75, up 0.98% on the day, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $4.68 versus $4.26 expected, driven by robust debt issuance and analytics demand. Revenue growth accelerated to 15% year-over-year, with net income margin expanding to 34.25%. The stock is supported by a consensus price target of $561.88, indicating 17.6% upside potential, and positive analyst sentiment with 56% buy ratings.

Outlook remains positive due to consistent earnings beats, high profitability, and strategic positioning in credit ratings. Risks include elevated valuation multiples, such as a P/E of 30.31, and dependence on capital market activity. Investors should weigh growth prospects against potential macroeconomic headwinds affecting debt issuance volumes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO